Opthea (ASX:OPT) said that there remained material uncertainty as to its ability to continue as a "going concern," according to a Wednesday Australian bourse filing.

The company noted it continues an active discussion with investors as required by a development funding agreement to explore possible options to deliver the best outcome for the firm and its shareholders.

The firm said it plans to use the net proceeds from any current or future offering or capital raise to advance clinical development, chemistry, manufacturing and controls, regulatory activities of any new asset, and for general corporate purposes.